APP and Alzheimer disease: Treatment with a brain-selective prodrug, DHED (10β,17β-dihydroxyestra-1,4-dien-3-one), in APP/PS1 double transgenic mice showed no systemic off-target effects in the uterine tissue, but similar improvements in APP levels, suggesting that the brain-selective treatment with DHED can be used as an early-stage intervention for AD (57).